Osteoporosis is a systematic skeletal disease characterized by low bone mass, increase of bone fragility and susceptibility to fracture.
Types of Osteoporosis and its causes
S.NO | Country/Region | Extrapolated Prevalence |
1 | USA | 10 million cases (80% cases are women and 20% cases are men) |
2 | Australia | 2.2 million |
3 | Middle east | 18,603,593 |
4 | Africa | 47,233,590 |
5 | Asia | 359,862,754 |
6 | Europe | 80,590,570 |
This is only a sample report with brief analysis
Dolcera can provide a comprehensive report customized to your needs
Generic | Brand | Current Status | Type | Company |
Antiresorptives | ||||
Bisphosphonates | ||||
Alendronate | FOSAMAX® | Approved by US | Postmenopausal | Merck |
Risedronate | Actonel® | Approved by US/ES | Postmenopausal | Sanofi-Aventis/Procter & Gamble |
Ibandronate | Boniva? | Approved by US | Postmenopausal | Roche |
Etidronate | Didronel | Off Label | Proctor And Gamble | |
Zoledronic Acid | Aclasta | Approved | Postmenopausal | Novartis |
Selective Estrogen Receptor Modulators | ||||
Raloxifene | Evista® | Approved by US | Osteoporosis | Eli lilly |
Hormone Replacement Therapy | ||||
Conjugated estrogen | Premarin® | Approved by US | Postmenopausal | Wyeth |
Conjugated estrogen | Cenestin? | Approved by US | Postmenopausal | Duramed |
Esterified estrogens | Estratab® | Approved by US | Postmenopausal | Solvay |
Esterified estrogens | Menesta | Approved by US | Postmenopausal | Monarch |
Estradiol Transdermal System | Menostar | Approved by US | Postmenopausal | Bayer |
Estradiol Transdermal System | Vivelle Dot | Approved by US | Postmenopausal | Noven |
Estradiol | Estrace® | Approved by US | Postmenopausal | Bristol-Myers Squibb |
Estradiol | Gynodiol | Approved by US | Postmenopausal | Novavax |
Tibolone | Livifem | Postmenopausal | ||
Calcitonin | ||||
Calcitonin Salmon Injection | Miacalcin® | Approved by US | Postmenopausal | Novartis |
Calcitonin Salmon Nasal Spray | Miacalcin® | Approved by US | Postmenopausal | Novartis |
Calcitonin Salmon Nasal Spray | Fortical® | Approved by US | Postmenopausal | |
Bone Forming Drugs | ||||
Teripratide | Forteo® | Approved by US | Osteoporosis | Pfizer |
Drugs with Complex Mechanisms of Action | ||||
Strontium Ranelate | Protelos | Not approved in USA | Postmenopausal osteoporosis | Servier |
Vitamin D | ||||
Calcium | FDA is considering amending rules so that companies can now claim that calcium and Vitamin D in their food supplements can prevent osteoprorosis in all ages and both sexes | FDA |
Product Pipeline | ||||
DRUG | COMPANY | DESCRIPTION | STAGE | |
RANKL Inhibitors | ||||
Denosumab | Atlantos, Amgen | A monoclonal antibody | 3 | |
Bisphosphonates | ||||
Minodronate (YM529) | Astellas | Nitrogen containing bisphosphonate | ||
Calcium Antagonist | ||||
423557 | Glaxosmithkline | 1 | ||
423562 | Glaxosmithkline | 1 | ||
Calcilytics (751689) | NPS and Glaxosmithkline | Calcilytics antagonize calcium receptors on parathyroid glands resulting in a transient release of the body?s own stores of parathyroid hormone (PTH). | 1 | |
Parathyroid Hormone | ||||
768974 | Glaxosmithkline | Parathyroid Hormone Agonist | 1 | |
Preos (rDNA origin) | NPS | Recombinant Parathyroid Hormone | Registration Filed | |
PTH1-34 | Nastech | Intranasal Parathyroid hormone | 2 | |
PTH1-34 | Novartis, Emisphere | Oral Parathyroid hormone | 1 | |
PTH Analogs | Unigene | 2 | ||
Cathepsin k Inhibitor | ||||
Relacatib (SB-462795) | GlaxoSmithkline | 1 | ||
AAE581 | Novartis | |||
MK-0822 | Canadian Institutes of Health Research, Merck | 2 | ||
Selective Estrogen Receptor Modulators | ||||
Bazedoxifene | Wyeth, Ligand | A Third-Generation Selective Estrogen Receptor Modulator for Treatment of Postmenopausal Osteoporosis | ||
Lasofoxifene (Oporia) | Pfizer,Ligand | A Third-Generation Selective Estrogen Receptor Modulator for Treatment of Postmenopausal Osteoporosis | NDA | |
Arzoxifene | Eli lilly | |||
Taromifene (Fareston) | Orion | |||
Calcitonin | ||||
Nastech | NDA | |||
Salmon calcitonin | Unigene | Nasal | 3 | |
Salmon calcitonin | Unigene | Oral | 2 | |
Salmon calcitonin (SMC 021) | Novartis, Emisphere, Nordic | Oral | 3 | |
Salmon calcitonin | Nobex (Biocon) | Oral | 3 | |
Vitamin D | ||||
ED 71 | Bone/ Chugai | Activted Vitamin D derivative | 3 | |
Doxercalciferol (Hectorol) | Bone Care Int. | Synthetic Vitamin D | ||
Nitrates: Research is going on to determine if nitrates can prevent osteoporosis in women. | ||||
Isosorbide mononitrate | St. Michael?s Hospital, Toronto | 3 | ||
Nitroglycerine | Canadian Institutes of Health Research (CIHR) | 3 | ||
HCT 1026 (NO releasing Derivative of NSAIDs) | NicOx SA | 2 | ||
Selective Androgen Receptor Modulator (SARM) | ||||
LGD-2941 | Ligand, TAP | 3 | ||
LGD-3303 | Ligand, TAP | 3 | ||
Ostarine | GTx | 2 | ||
Intermittent Versus Continuous Androgen Suppression | Ontario Cancer Research Network | |||
Mk 0733 | Merck | 1 | ||
TH0229 | Theratechnologies | |||
c-8500 | Merck | 2 | ||
c-3578 | Merck | 2 | ||
apomorphine | Ilex Oncology | 2 | ||
Genistein | Primus Pharmaceuticals, Inc. | isoflavones have been shown to interact with animal and human estrogen receptors, causing effects in the body similar to those caused by the hormone estrogen. | Available | |
Soy estrogens | (NIAMS) | 3 | ||
Hesperidin | Nestle clinical nutrition | 3 | ||
Davallia Divaricata | National Taiwan University Hospital | 1 | ||
Atorvaststin | [1] | |||
Potassium citrate | Weill Medical College of Cornell University | 4 | ||
Phosphorus | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 3 |
Hip Protector | Hip pads with special underwear with pockets | Children?s Mercy Hospital Kansas City |
Prescription Trends in USA | |||||||||
Source: Arch Intern Med. 2004;164:1525-1530 | |||||||||
1988 | 1990 | 1992 | 1994 | 1996 | 1998 | 2000 | 2002 | 2003 | |
Patients (Millions) | NA | 0.6 | 0.6 | 0.5 | 1.2 | 2 | 2.6 | 2.8 | 3.6 |
Drugs Prescribed % | |||||||||
Bisphosphonates (total) | 1 | 9 | 17 | 14 | 48 | 49 | 54 | 71 | 73 |
Alendronate | 0 | 0 | 0 | 0 | 45 | 47 | 48 | 53 | 51 |
Risedronate | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 17 | 22 |
Etidronate | 1 | 9 | 17 | 14 | 3 | 1 | 1 | 0 | 0 |
Calcium | 39 | 33 | 33 | 43 | 31 | 26 | 29 | 26 | 24 |
Calcitonins | 5 | 9 | 10 | 13 | 13 | 16 | 15 | 7 | 5 |
Estrogens | 35 | 25 | 33 | 27 | 17 | 12 | 8 | 5 | 3 |
SERMs | 0 | 0 | 0 | 0 | 0 | 9 | 14 | 12 | 12 |
Trial No. | Condition | Description | Intervention | Therapy | Route of admn | Sponsors & Collaborators | Phase | Date |
1 | Postmenopausal Osteoporosis | Investigate Patient Preference On Dosing In Ibandronate And Risedronate in korean women | Ibandronate | Drug | Oral | GlaxoSmithKline | Phase IV | May-07 |
2 | Osteoporosis Osteopenia |
Texture Analysis for Postmenopausal Osteoporosis | Alendronate | Drug | Oral | University of Chicago | - | Mar-07 |
3 | Osteoporosis | A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis. | SB-751689 | Drug | Oral | GlaxoSmithKline | Phase II | May-07 |
4 | Osteoporosis | Fall prevention program | Procedure | - | - | Sint Maartenskliniek ZonMw: The Netherlands Organisation for Health Research and Development |
Apr-07 | |
5 | Osteoporosis Osteopenia |
High Dosage Vitamin D and Osteoporosis | Cholecalciferol | Drug | Oral | University Hospital of North Norway | Phase IV | Jun-07 |
6 | Osteoporosis | Effect of PTH(1-84)or Strontium Ranelate on Bone Formation Measured by Bone Markers | Parathyronine hormone | Drug | Oral | Nycomed | Phase IV | May-07 |
7 | Post-Menopausal Osteoporosis | A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis. | ibandronate [Bonviva/Boniva] | Drug | Intravenous | Hoffmann-La Roche | Phase IV | Jul-07 |
8 | Osteoporosis | A Study for Patients With Osteoporosis | 1.Salmon Calcitonin 2.Teriparatide | Drug | Nose/intravenous | Eli Lilly and Company | Phase III |
Jun-07 |
9 | Osteoporosis | Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Post Menopausal Women With Osteoporosis | Zoledronic acid and alendronate | Drug | Oral | Novartis | Phase III |
May-07 |
10 | Osteoporosis | Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis | zoledronic acid | Drug | Intravenous | Novartis | Phase III |
Feb-07 |
11 | Osteoporosis | Davallia Divaricata BL: The Use of Traditional Chinese Native Medicine for Osteoporosis | Gu-Sui-Bu (Davallia Divaricata) | Drug | National Taiwan University Hospital | Phase I |
Jan-07 | |
12 | Osteoporosis | Dose Ranging Study - Macroflux PTH in Postmenopausal Women With Osteoporosis | Macroflux PTH | Drug | Subcutaneuos | The Macroflux Corporation | Phase II | Jun-07 |
13 | Osteoporosis | Fosamax for Childhood Cancer Survivors | Alendronate | Drug | Oral | Chinese University of Hong Kong | Phase III | Oct-06 |
14 | Osteoporosis | This study is currently recruiting patients. | Parathyroid Hormone (PTH) | Drug | Subcutaneuos | Nycomed | - | Feb-07 |
15 | Osteoporosis | This study is currently recruiting patients. | Alendronate with cholecalciferol and Os-Cal with extra D | Drug | Oral | National Institute on Aging (NIA),Glaxosmithkline | Phase III | May-07 |
16 | Primary Osteoporosis | Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis | Ibandronic acid | Drug | Oral | Chugai Pharmaceutical | Phase III | Mar-07 |
17 | Postmenopausal Osteoporosis, Back pain and Spinal Fracture |
Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis | Teriparatide and risedronate | Drug | Oral/Subcutaneuos | Eli Lilly and Company | Phase III | Jul-07 |
18 | Osteoporosis | BONDIR Study: A Study of Intravenous Bonviva (Ibandronate) After Recent Vertebral Osteoporotic Fracture in Patients With Osteoporosis. | Ibandronate [Bonviva/Boniva] | Drug | Intravenous | Hoffmann-La Roche | Phase III | Jul-07 |
This is only a sample report with brief analysis
Dolcera can provide a comprehensive report customized to your needs
Samir Raiyani |
---|
Email: info@dolcera.com |
Phone: +1-650-269-7952 |